Sp1294

BOWEL URGENCY IN ULCERATIVE COLITIS

Date
May 7, 2023

Society: DDW

Sponsored by Lilly USA

Presenter

Speaker Image for J. Casey Chapman

Speakers

Speaker Image for Stephen Hanauer
Northwestern Feinberg School of Medicine
Speaker Image for Angelina Collins

Tracks

Related Products

Thumbnail for AGA Farron and Martin Brotman, MD, Lecture — Transforming IBD Care 1: The Biologic Revolution — Past, Present and Future
AGA Farron and Martin Brotman, MD, Lecture — Transforming IBD Care 1: The Biologic Revolution — Past, Present and Future
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Thumbnail for Farron and Martin Brotman, MD, Lecture — IBD in 2025: Reviewing a Quarter Century of Progress
Farron and Martin Brotman, MD, Lecture — IBD in 2025: Reviewing a Quarter Century of Progress
The landscape of treatment for IBD has evolved significantly over the past two decades. This session will examine advances in our understanding of disease pathogenesis and review treatment paradigm changes…
Thumbnail for SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Thumbnail for UNDERSTANDING ZYMFENTRA: THE FIRST AND ONLY SUBCUTANEOUS INFLIXIMAB OFFERING A NEW THERAPEUTIC APPROACH IN CD AND UC MAINTENANCE